Axa Investment Managers S.A. Arcus Biosciences, Inc. Transaction History
Axa Investment Managers S.A.
- $35.5 Billion
- Q3 2025
A detailed history of Axa Investment Managers S.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Axa Investment Managers S.A. holds 232,668 shares of RCUS stock, worth $4.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
232,668Holding current value
$4.67 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
211Shares Held
67.7MCall Options Held
3.3MPut Options Held
146K-
Black Rock Inc. New York, NY9.76MShares$196 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.63MShares$133 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.33MShares$87 Million0.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.77MShares$75.7 Million0.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74 Million1.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.45B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...